The overall goal of this project was to develop, optimize, and test an ultrasound-responsive targeted nanobubble for delivering osteoporosis-related silencing genes such as Cathepsin K small interfering RNA (CTSK siRNA) for osteoporosis treatment. The nanobubbles were synthesized using an in situ sonochemical method. The nanobubble (NB) is composed of a gas core made from perfluorocarbon, stabilized with albumin, encapsulated with CTSK siRNA, and embedded with alendronate (AL) for bone targeting (CTSK siRNA-NB-AL). Following its development, the responsiveness of CTSK siRNA-NB-AL to a therapeutic ultrasound probe was examined. The results of biocompatibility tests with human bone marrow-derived mesenchymal stem cells proved no significant cell death (p > 0.05). When the CTSK siRNA-NB-AL was supplemented with human osteoclast precursors, they suppressed osteoclastogenesis. Thus, this project establishes the potential of nanotechnology and ultrasound to deliver genes into the osteoclasts. This research also presents a novel ultrasound responsive and targeted nanobubble platform that can be used as a gene, drug, and/or oxygen delivery system for various diseases including cancer, neurodegenerative diseases, or bone disorders.
Bachelor of Science (B.S.)
College of Medicine
Burnett School of Biomedical Sciences
Length of Campus-only Access
Shar, Angela, "Developing a Targeted Ultrasound-responsive Nanobubble-based Gene Delivery System for Osteoporosis Treatment" (2021). Honors Undergraduate Theses. 1045.